Abstract
Since the early days of gene therapy, muscle has been one the most studied tissue targets for the correction of enzyme deficiencies and myopathies. Several preclinical and clinical studies have been conducted using adeno-associated virus (AAV) vectors. Exciting progress has been made in the gene delivery technologies, from the identification of novel AAV serotypes to the development of novel vector delivery techniques. In parallel, significant knowledge has been generated on the host immune system and its interaction with both the vector and the transgene at the muscle level. In particular, the role of underlying muscle inflammation, characteristic of several diseases affecting the muscle, has been defined in terms of its potential detrimental impact on gene transfer with AAV vectors. At the same time, feedback immunomodulatory mechanisms peculiar of skeletal muscle involving resident regulatory T cells have been identified, which seem to play an important role in maintaining, at least to some extent, muscle homeostasis during inflammation and regenerative processes. Devising strategies to tip this balance towards unresponsiveness may represent an avenue to improve the safety and efficacy of muscle gene transfer with AAV vectors.
Keywords: AAV vectors, Muscle, Clinical trials, Immune responses, Tolerance.
Current Gene Therapy
Title:The Skeletal Muscle Environment and Its Role in Immunity and Tolerance to AAV Vector-Mediated Gene Transfer
Volume: 15 Issue: 4
Author(s): Florence Boisgerault and Federico Mingozzi
Affiliation:
Keywords: AAV vectors, Muscle, Clinical trials, Immune responses, Tolerance.
Abstract: Since the early days of gene therapy, muscle has been one the most studied tissue targets for the correction of enzyme deficiencies and myopathies. Several preclinical and clinical studies have been conducted using adeno-associated virus (AAV) vectors. Exciting progress has been made in the gene delivery technologies, from the identification of novel AAV serotypes to the development of novel vector delivery techniques. In parallel, significant knowledge has been generated on the host immune system and its interaction with both the vector and the transgene at the muscle level. In particular, the role of underlying muscle inflammation, characteristic of several diseases affecting the muscle, has been defined in terms of its potential detrimental impact on gene transfer with AAV vectors. At the same time, feedback immunomodulatory mechanisms peculiar of skeletal muscle involving resident regulatory T cells have been identified, which seem to play an important role in maintaining, at least to some extent, muscle homeostasis during inflammation and regenerative processes. Devising strategies to tip this balance towards unresponsiveness may represent an avenue to improve the safety and efficacy of muscle gene transfer with AAV vectors.
Export Options
About this article
Cite this article as:
Boisgerault Florence and Mingozzi Federico, The Skeletal Muscle Environment and Its Role in Immunity and Tolerance to AAV Vector-Mediated Gene Transfer, Current Gene Therapy 2015; 15 (4) . https://dx.doi.org/10.2174/1566523215666150630121750
DOI https://dx.doi.org/10.2174/1566523215666150630121750 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Hepatitis C Virus-Associated B-Cell Non-Hodgkin's Lymphoma: Clinical and Therapeutic Challenges
Current Drug Targets Phosphodiesterase 4 Inhibitors in Inflammatory Bowel Disease: A Comprehensive Review
Current Pharmaceutical Design Recent Gains in Clinical Multiple Sclerosis Research
CNS & Neurological Disorders - Drug Targets The Role of Endothelial Dysfunction in Aortic Aneurysms
Current Pharmaceutical Design Immediate and Late Adverse Reactions to Iodinated Contrast Media: A Pharmacological Point of View
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Mechanisms of Neurodegeration in Type 2 Diabetes and the Neuroprotective Potential of Dipeptidyl Peptidase 4 Inhibitors
Current Medicinal Chemistry Cell Cycle Arrest as a Therapeutic Target of Acute Kidney Injury
Current Protein & Peptide Science Drugs, Trials and Pathogenesis: Will Connecting these Help us Understand SLE?
Current Rheumatology Reviews The Chemical Defensive System in the Pathobiology of Idiopathic Environment- Associated Diseases
Current Drug Metabolism Activation of the Liver X Receptor Inhibits Th17 and Th1 Responses in Behcet`s Disease and Vogt-Koyanagi-Harada Disease
Current Molecular Medicine The Role of Nuclear Receptor PPARα in the Sleep-wake Cycle Modulation. A Tentative Approach for Treatment of Sleep Disorders
Current Drug Delivery A Review of the Potential Receptors of Migraine with a Special Emphasis on CGRP to Develop an Ideal Antimigraine Drug
Current Molecular Pharmacology Depression as a Comorbidity in Behcet's Syndrome
CNS & Neurological Disorders - Drug Targets Adverse Cardiovascular Effects of Antirheumatic Drugs: Implications for Clinical Practice and Research
Current Pharmaceutical Design Novel Therapeutic Targets for Somatostatin in Inflammatory Chronic Diseases
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Natural Compounds with Proteasome Inhibitory Activity for Cancer Prevention and Treatment
Current Protein & Peptide Science Lectin-Like Oxidized Low Density Lipoprotein Receptor 1 (LOX-1) in Atherogenesis: A Brief Review
Current Medicinal Chemistry The Risk of Progressive Multifocal Leukoencephalopathy Under Biological Agents Used in the Treatment of Chronic Inflammatory Diseases
Inflammation & Allergy - Drug Targets (Discontinued) The Protective Effects of Natural Products on Blood-Brain Barrier Breakdown
Current Medicinal Chemistry Subject Index to Volume 10
Current Pharmaceutical Design